NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. (NAMS) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for NewAmsterdam Pharma Company N.V. (NAMS), covering cash flow, earnings, and balance sheets.
NewAmsterdam Pharma Company N.V. (NAMS) Income Statement & Financial Overview
Review NewAmsterdam Pharma Company N.V. NAMS income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $2.98M | $12.77M | $29.11M | $2.28M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $2.98M | $12.77M | $29.11M | $2.28M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $44.75M | $34.90M | $35.70M | $38.38M |
| SG&A Expenses | $27.15M | $24.31M | $17.28M | $15.30M |
| Operating Expenses | $71.90M | $56.001M | $54.11M | $54.85M |
| Total Costs & Expenses | $71.90M | $56.001M | $54.11M | $54.85M |
| Interest Income | $7.35M | $4.49M | $4.44M | $4.87M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $52000.00 | $51000.00 | $28000.00 | $19000.00 |
| EBITDA | -$68.87M | -$111.69M | -$23.84M | -$51.38M |
| EBITDA Ratio | -$23.13 | -$8.75 | -$0.82 | -$22.54 |
| Operating Income | -$68.92M | -$43.23M | -$25.003M | -$52.58M |
| Operating Income Ratio | -$23.14 | -$3.38 | -$0.86 | -$23.07 |
| Other Income/Expenses (Net) | $29.40M | -$48.95M | $8.36M | $13.57M |
| Income Before Tax | -$39.53M | -$92.18M | -$16.65M | -$39.007M |
| Income Before Tax Ratio | -$13.27 | -$7.22 | -$0.57 | -$17.12 |
| Income Tax Expense | $0.00 | $0.00 | -$1000.00 | $0.00 |
| Net Income | -$39.53M | -$92.18M | -$16.65M | -$39.007M |
| Net Income Ratio | -$13.27 | -$7.22 | -$0.57 | -$17.12 |
| EPS | -$0.34 | -$0.98 | -$0.18 | -$0.38 |
| Diluted EPS | -$0.34 | -$0.98 | -$0.18 | -$0.38 |
| Weighted Avg Shares Outstanding | $116.12M | $97.03M | $94.75M | $94.71M |
| Weighted Avg Shares Outstanding (Diluted) | $116.12M | $97.03M | $94.75M | $94.71M |
Over the past four quarters, NewAmsterdam Pharma Company N.V. demonstrated steady revenue growth, increasing from $2.28M in Q2 2024 to $2.98M in Q1 2025. Operating income reached -$68.92M in Q1 2025, maintaining a consistent -2314% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$68.87M, reflecting operational efficiency. Net income rose to -$39.53M, with EPS at -$0.34. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan